Business Model Breakdown
How Intellia Therapeutics Inc Makes Money
NTLA
Market Cap
$1.8B
Annual Revenue
$58M
Profit Margin
-597.0%
The Short Version
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative gene-editing treatments using its proprietary CRISPR/Cas9 technology. It makes money primarily through collaboration agreements with larger pharmaceutical companies, which provide upfront payments, research funding, and potential milestone payments and royalties on future product sales. As its lead drug candidates like lonvo-z (for hereditary angioedema) approach commercialization, the company expects to generate product revenue from direct sales upon regulatory approval. The business model relies on leveraging its gene-editing platform to create a pipeline of therapies, partnering to share development costs and expertise, and ultimately commercializing these therapies for patients with severe genetic diseases.
Where the Revenue Comes From
Collaboration revenue (~100% of current revenue, $15.0 million in Q1 2026)
Potential future product revenue (post-launch of lonvo-z in 1H 2027)
Who buys: Pharmaceutical partners (currently); eventually patients with severe genetic diseases (e.g., hereditary angioedema, ATTR amyloidosis), healthcare providers, and payers.
Why It Works (Competitive Advantages)
- ✔Proprietary in vivo CRISPR/Cas9 delivery platform (LNP) for direct administration.
- ✔Strong IP portfolio around CRISPR-Cas9 for in vivo applications.
- ✔Clinical lead in specific indications like HAE with lonvo-z.
Economic Moat: Narrow (Intangible Assets/IP (CRISPR gene-editing technology, LNP delivery system, specific guide RNA sequences))
What Our Analysis Says
DVR Score as of June 10, 2026
Intellia Therapeutics continues to demonstrate strong execution in its pioneering gene-editing pipeline. The positive Phase 3 data for lonvo-z in HAE and the initiation of its rolling BLA submission, targeting a 1H 2027 launch, are transformative. The FDA's lifting of clinical holds on nex-z trials further de-risks its broader platform. While the company remains unprofitable, its Q1 2026 earnings beat consensus and its cash runway is extended into 2028 via strategic dilution. This positions Intellia as a clear leader in a groundbreaking field with substantial market opportunities. The strategic positioning, robust IP, and a clear path to commercialization for a potentially curative therapy underscore its high-risk, high-reward 10x growth potential, despite the inherent financial risks of a clinical-stage biotech.